Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials

Miguel Regueiro, Edward Vincent Loftus, Jr, A. Hillary Steinhart, Russell D. Cohen

Research output: Contribution to journalReview article

89 Citations (Scopus)

Abstract

BACKGROUND: The goal of this work was to critically evaluate the published studies on the treatment of ulcerative proctitis (UP) and left-sided ulcerative colitis (L-UC). The results of this review provided the content for the accompanying treatment guidelines, Clinical Guidelines for the Medical Management of Left-sided Ulcerative Colitis and Ulcerative Proctitis: Summary Statement. METHODS: All English language articles published between 1995 and September 2005 were identified through a comprehensive literature search using OVID and PubMed. The quality of the data supporting or rejecting the use of specific therapies was categorized by a data quality grading scale. An "A+" grade was assigned to treatment supported by multiple high-quality randomized controlled trials with consistent results, whereas a "D" grade was given to therapy supported only by expert opinion. The therapeutic efficacy of a treatment was defined by its success in treating UP and L-UC compared with placebo. A medication was ranked as "excellent" if it was specifically studied for UP and L-UC and had consistently positive results compared with placebo or another agent. Quality and efficacy scores were agreed on by author consensus. RESULTS: For the acute treatment of UP or L-UC, the rectally administered corticosteroids and mesalazine (5-ASA), either alone or in combination with oral 5-ASAs, are the most effective therapy: evidence quality, A+; efficacy, excellent. Only rectally administered 5-ASA received an A+/excellent rating for maintenance of remission. Infliximab received an A+ grade for induction and maintenance of remission but only a "good" rating because the studies were performed in all UC, not specifically UP or L-UC. CONCLUSIONS: This critical evaluation of treatment provides a "report card" on medications available for the management of patients with UP and L-UC. The guidelines should provide a useful reference and supplement for physicians treating UC patients.

Original languageEnglish (US)
Pages (from-to)979-994
Number of pages16
JournalInflammatory Bowel Diseases
Volume12
Issue number10
DOIs
StatePublished - Oct 2006

Fingerprint

Proctitis
Ulcerative Colitis
Therapeutics
Guidelines
Placebos
Maintenance
Remission Induction
Mesalamine
Expert Testimony
PubMed
Consensus
Adrenal Cortex Hormones
Language
Randomized Controlled Trials
Physicians

Keywords

  • 5-aminosalicylic acid
  • Biologic response modifiers
  • Colitis
  • Corticosteroids
  • Distal ulcerative colitis
  • Immunomodulators
  • Infliximab
  • Left sided ulcerative
  • Medical management
  • Medical therapy
  • Medical treatment
  • Ulcerative colitis
  • Ulcerative proctitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Medical management of left-sided ulcerative colitis and ulcerative proctitis : Critical evaluation of therapeutic trials. / Regueiro, Miguel; Loftus, Jr, Edward Vincent; Steinhart, A. Hillary; Cohen, Russell D.

In: Inflammatory Bowel Diseases, Vol. 12, No. 10, 10.2006, p. 979-994.

Research output: Contribution to journalReview article

@article{4a971761bd264e2c87ce709c75ba46ee,
title = "Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials",
abstract = "BACKGROUND: The goal of this work was to critically evaluate the published studies on the treatment of ulcerative proctitis (UP) and left-sided ulcerative colitis (L-UC). The results of this review provided the content for the accompanying treatment guidelines, Clinical Guidelines for the Medical Management of Left-sided Ulcerative Colitis and Ulcerative Proctitis: Summary Statement. METHODS: All English language articles published between 1995 and September 2005 were identified through a comprehensive literature search using OVID and PubMed. The quality of the data supporting or rejecting the use of specific therapies was categorized by a data quality grading scale. An {"}A+{"} grade was assigned to treatment supported by multiple high-quality randomized controlled trials with consistent results, whereas a {"}D{"} grade was given to therapy supported only by expert opinion. The therapeutic efficacy of a treatment was defined by its success in treating UP and L-UC compared with placebo. A medication was ranked as {"}excellent{"} if it was specifically studied for UP and L-UC and had consistently positive results compared with placebo or another agent. Quality and efficacy scores were agreed on by author consensus. RESULTS: For the acute treatment of UP or L-UC, the rectally administered corticosteroids and mesalazine (5-ASA), either alone or in combination with oral 5-ASAs, are the most effective therapy: evidence quality, A+; efficacy, excellent. Only rectally administered 5-ASA received an A+/excellent rating for maintenance of remission. Infliximab received an A+ grade for induction and maintenance of remission but only a {"}good{"} rating because the studies were performed in all UC, not specifically UP or L-UC. CONCLUSIONS: This critical evaluation of treatment provides a {"}report card{"} on medications available for the management of patients with UP and L-UC. The guidelines should provide a useful reference and supplement for physicians treating UC patients.",
keywords = "5-aminosalicylic acid, Biologic response modifiers, Colitis, Corticosteroids, Distal ulcerative colitis, Immunomodulators, Infliximab, Left sided ulcerative, Medical management, Medical therapy, Medical treatment, Ulcerative colitis, Ulcerative proctitis",
author = "Miguel Regueiro and {Loftus, Jr}, {Edward Vincent} and Steinhart, {A. Hillary} and Cohen, {Russell D.}",
year = "2006",
month = "10",
doi = "10.1097/01.mib.0000231495.92013.5e",
language = "English (US)",
volume = "12",
pages = "979--994",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Medical management of left-sided ulcerative colitis and ulcerative proctitis

T2 - Critical evaluation of therapeutic trials

AU - Regueiro, Miguel

AU - Loftus, Jr, Edward Vincent

AU - Steinhart, A. Hillary

AU - Cohen, Russell D.

PY - 2006/10

Y1 - 2006/10

N2 - BACKGROUND: The goal of this work was to critically evaluate the published studies on the treatment of ulcerative proctitis (UP) and left-sided ulcerative colitis (L-UC). The results of this review provided the content for the accompanying treatment guidelines, Clinical Guidelines for the Medical Management of Left-sided Ulcerative Colitis and Ulcerative Proctitis: Summary Statement. METHODS: All English language articles published between 1995 and September 2005 were identified through a comprehensive literature search using OVID and PubMed. The quality of the data supporting or rejecting the use of specific therapies was categorized by a data quality grading scale. An "A+" grade was assigned to treatment supported by multiple high-quality randomized controlled trials with consistent results, whereas a "D" grade was given to therapy supported only by expert opinion. The therapeutic efficacy of a treatment was defined by its success in treating UP and L-UC compared with placebo. A medication was ranked as "excellent" if it was specifically studied for UP and L-UC and had consistently positive results compared with placebo or another agent. Quality and efficacy scores were agreed on by author consensus. RESULTS: For the acute treatment of UP or L-UC, the rectally administered corticosteroids and mesalazine (5-ASA), either alone or in combination with oral 5-ASAs, are the most effective therapy: evidence quality, A+; efficacy, excellent. Only rectally administered 5-ASA received an A+/excellent rating for maintenance of remission. Infliximab received an A+ grade for induction and maintenance of remission but only a "good" rating because the studies were performed in all UC, not specifically UP or L-UC. CONCLUSIONS: This critical evaluation of treatment provides a "report card" on medications available for the management of patients with UP and L-UC. The guidelines should provide a useful reference and supplement for physicians treating UC patients.

AB - BACKGROUND: The goal of this work was to critically evaluate the published studies on the treatment of ulcerative proctitis (UP) and left-sided ulcerative colitis (L-UC). The results of this review provided the content for the accompanying treatment guidelines, Clinical Guidelines for the Medical Management of Left-sided Ulcerative Colitis and Ulcerative Proctitis: Summary Statement. METHODS: All English language articles published between 1995 and September 2005 were identified through a comprehensive literature search using OVID and PubMed. The quality of the data supporting or rejecting the use of specific therapies was categorized by a data quality grading scale. An "A+" grade was assigned to treatment supported by multiple high-quality randomized controlled trials with consistent results, whereas a "D" grade was given to therapy supported only by expert opinion. The therapeutic efficacy of a treatment was defined by its success in treating UP and L-UC compared with placebo. A medication was ranked as "excellent" if it was specifically studied for UP and L-UC and had consistently positive results compared with placebo or another agent. Quality and efficacy scores were agreed on by author consensus. RESULTS: For the acute treatment of UP or L-UC, the rectally administered corticosteroids and mesalazine (5-ASA), either alone or in combination with oral 5-ASAs, are the most effective therapy: evidence quality, A+; efficacy, excellent. Only rectally administered 5-ASA received an A+/excellent rating for maintenance of remission. Infliximab received an A+ grade for induction and maintenance of remission but only a "good" rating because the studies were performed in all UC, not specifically UP or L-UC. CONCLUSIONS: This critical evaluation of treatment provides a "report card" on medications available for the management of patients with UP and L-UC. The guidelines should provide a useful reference and supplement for physicians treating UC patients.

KW - 5-aminosalicylic acid

KW - Biologic response modifiers

KW - Colitis

KW - Corticosteroids

KW - Distal ulcerative colitis

KW - Immunomodulators

KW - Infliximab

KW - Left sided ulcerative

KW - Medical management

KW - Medical therapy

KW - Medical treatment

KW - Ulcerative colitis

KW - Ulcerative proctitis

UR - http://www.scopus.com/inward/record.url?scp=33749370428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749370428&partnerID=8YFLogxK

U2 - 10.1097/01.mib.0000231495.92013.5e

DO - 10.1097/01.mib.0000231495.92013.5e

M3 - Review article

C2 - 17012969

AN - SCOPUS:33749370428

VL - 12

SP - 979

EP - 994

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 10

ER -